Since the introduction of penicillin in 1942, antimicrobials have transformed the treatment of infections and saved millions of lives. But organisms “resistant” to penicillin were noticed from almost the very beginning. Now, decades of misuse and outdated guidelines have driven a rise in the organisms that are resistant to these lifesaving drugs.
Antimicrobial resistance (AMR) is the ability of miroorganisms (including bacteria, fungi, viruses, etc.) to nullify the effects of antimicrobial drugs, resulting in these drugs becoming ineffective.1,2 AMR can affect anyone, of any age, in any country. 1
Today, AMR is one of the world’s greatest health threats, causing over 1 million deaths each year, and that number is growing.3
As the problem continues, common medical procedures will become increasingly life-threatening. Left unabated, the problem will grow exponentially, literally threatening every person on earth.
1. High number of bacteria
Whenever there is a high number of bacteria, a small number of them are resistant to antibiotics.
2. Antibiotics kill bacteria
When taken, antibiotics kill bacteria causing the illness but they also kill the good bacteria that protect the body from infection.
3. Resistant bacteria grow and multiply
The resistant bacteria can now grow and multiply without competition.
4. Transfer of resistance
Some bacteria can transfer their resistance to antibiotics to other bacteria, which can cause more problems.
If left unabated, the effects of AMR could be worse than COVID-19. 6,11 Future projections suggest that AMR could result in millions of deaths and trillions of dollars in lost global production. 7
As the problem continues, common medical procedures will become increasingly life-threatening. The problem can grow exponentially, literally threatening every person on earth.
Our global public health efforts seek to expand access and drive capacity-building through partnerships with leading organizations and governments.
We engage in advocacy with governments, funders and health agencies to advance innovations to address the world’s leading public health needs, including drug-resistant infections.
We possess important capabilities that are instrumental in containing AMR. We offer a wide range of medical products, platforms and offerings that can be used to prevent the spread of infection in healthcare facilities, such as diagnostic systems to screen, test and diagnose infection, including drug-resistant strains, as well as state-of-the-art surveillance and reporting capabilities to monitor, track and predict AMR outbreaks.
Enabled by our innovative programs and technologies, BD teams across the globe are directly engaging AMR leaders in government, academia and professional societies to strengthen AMR awareness, health systems, capacities and infection prevention and diagnostic practices.
1. World Health Organization. Antimicrobial resistance fact sheet. http://www.who.int/mediacentre/factsheets/fs194/en/. Accessed November 28, 2017.
2. Centers for Disease Control and Prevention. About antimicrobial resistance. https://www.cdc.gov/drugresistance/about.html. Accessed May 12, 2017.
3. Institute for Health Metrics and Evaluation. The latest estimates of global anti-microbial resistance showurgent policy action is needed to save lives. https://www.healthdata.org/news-release/latest-estimatesglobal-anti-microbial-resistance-show-urgentpolicyactionneededsave#:~:text=An%20estimated%204.95 %20million%20people,young%20children%20are%20particularly%20affected. Accessed February 8, 2022.
4. World Health Organization. Ten threats to global health in 2019. https://www.who.int/news-room/spotlight/ten-threats-toglobal-health-in-2019. Accessed February 8, 2022.
5. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629-655.
6. Centers for Disease Control and Prevention. More people in the United States dying from antibioticresistant infections than previously estimated. https://www.cdc.gov/media/releases/2019/p1113-antibioticresistant. html; Accessed June 23, 2022.
7. O’Neill J. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. https://amrreview.
for%20the%20health%20and%20wealth%20of%20nations_1.pdf. Accessed February 8, 2022.
8. Smith R, Coast J. The true cost of antimicrobial resistance. BMJ. 2013;346:f1493.
9. World Bank. By 2050, drug-resistant infections could cause global economic damage on par with 2008
financial crisis, http://www.worldbank.org/en/news/press-release/2016/09/18. Accessed October 12, 2017.
10. Shapiro DJ, Hicks LA, Pavia AT, Hersh AL. Antibiotic prescribing for adults in ambulatory care in the USA,
2007–09. J Antimicrob Chemother. 2013;69(1):234-240.
11. Ukuhor H. The interrelationships between antimicrobial resistance, COVID-19, past, and future
pandemics. J Infect Public Health. 2021;14(1):53-60.
SHEA: In support of the infection prevention efforts of the Society for Healthcare Epidemiology of America (SHEA), BD provides an educational grant for the “Prevention Course in HAI Knowledge and Control”—a free educational resource to keep frontline providers, their families, and patients safe.
International Collaboration: BD has worked with national governments in multiple countries, including the United States, China, Kenya, Cambodia, and India, via public-private partnerships to improve hospitals’ capabilities with infection prevention and control.
Educational Publication Partnerships: BD leverages expertise from internal clinical pharmacists, infectious disease physicians and industry-leading data scientists to produce more than 500 unique analytic tool sets, resulting in publications informing infection prevention guidelines.
Working together to improve processes: BD partners with clinicians in addressing vascular access-related complications by identifying gaps in their current vascular access process.
Integrated Vascular Access Management
Vascular access management is vital to help reduce complications and infections, and to improve patient outcomes.
Standardized Surgical Preparation Procedures
Preoperative skin preparation is an important step in helping to limit surgical wound contamination and prevent infection.
Critical Care Solutions
Products and kits designed to reduce variability or improve compliance in critical care practice.
Globally: BD is working with The Fleming Fund to strengthen laboratories in 19 developing and emerging countries.
BD partnered with the Foundation for Innovative New Diagnostics (FIND), a Geneva-based non-governmental organization, to develop the new AMR scorecard for lab quality improvement. A successful rollout of equipment, reagents and training has improved lab capabilities across these countries.
UK: BD partnered with a UK pharmacy chain to demonstrate the effective use of point-of-care tests that diagnose patients with viral infections, resulting in the reduction of the number of unnecessary antibiotic prescriptions.
India: BD partnered with the Ministry of Health in Kerala to increase access to automated blood culture and identification and antibiotic susceptibility technologies at a secondary public sector hospital, to reduce mortality rates due to sepsis.
Improve sample quality and protect specimen integrity by properly acquiring and managing samples for testing.
Accurate Patient Screening
Reduce the risk of HAIs by efficiently identifying patients colonized with resistant organisms.
Rapid Detection and Identification of Infectious Agents
Guide therapy and prevent unnecessary antimicrobial use by identifying the cause of infection.
Precise Susceptibility Testing
Optimize the patient treatment plan by determining the specific antimicrobials that inhibit or kill particular bacteria.
BD has contributed extensive data and analytics to evaluate and report the burden of AMR to a range of global organizations, including the:
The BD Health and Economic Outcomes Research (HEOR) team developed an AMR Burden of Disease Tool that illustrates current and anticipated future clinical and economic impacts of AMR across various system levels. BD is helping health systems and facilities in Canada, Southeast Asia, China and elsewhere use this tool.
The BD HealthSight™ platform transforms over 2.3 billion patient messages per year into meaningful analytics and insights for clients, BD business units and the scientific community/industry. We collaborate with other life science companies to publish these critical data sets.
Enhanced infection surveillance and analytics
Empower health systems to identify and report infections, translate data into a tool for HAI management and detect possible outbreaks and clusters of resistant organisms and other important pathogens.
Streamlined antimicrobial use and resistance reporting
Enhances efforts through on-demand, standardized evaluation and reporting of antimicrobial use and resistance.
Enterprise inventory optimization
Supports patient care by providing facilities with visibility to their medications through a central view of inventory, orders and usage across the health system.